7210 Wareham Drive, Tampa, FL 33647
Dec. 30, 2023 We have started to see TV commercials touting a company called RO, for weight loss. Apparently, this company entered the weight loss market in January 2023, providing GLP-1 weight loss drugs plus coaching, Ro is a direct-to-patient healthcare company with a mission of helping patients achieve their health goals by delivering the […]
New Competitor – RO.co (Roman Health Ventures) Read More »
Dec. 14, 2023 Medifast on Wednesday marked its first entry into the medically supported weight loss market through a collaboration with LifeMD Inc., a provider of virtual primary care. This venture brings together Optavia’s personalized, coach-guided approach with medical expertise from board-certified LifeMD clinicians and access to weight loss medications, including GLP-1s. Medifast has committed
Medifast Enters Medical Weight Loss Market Read More »
Sept. 13, 2023 On August 8, Lilly reported that its second-quarter income jumped 85% from the same period a year ago, driven in large part by Mounjaro, which generated $979.7 million in sales for the quarter, compared to $16 million in the year-ago period and $569 million in the first quarter of this year. In
Obesity Drug Sales Continue To Soar Read More »
August 20, 2023 Boehringer Ingelheim could soon stake a claim in the lucrative obesity treatment market after the pharma company said it has advanced a candidate into three Phase III trials following promising data. Servodutide, the company’s glucagon/glucagon-like peptide 1 (GLP-1) receptor dual agonist co-developed with Zeland Pharma, demonstrated up to 19% weight loss after
More Obesity Drugs in the Pipeline – Boehringer Ingelheim Read More »
Aug. 8, 2023 Second quarter 2023 revenue decreased 34.7% to $296.2 million from $453.3 million for the second quarter of 2022, primarily driven by a decrease in the number of active earning OPTAVIA Coaches and the decline in the productivity per active earning OPTAVIA Coach. The average revenue per active earning OPTAVIA Coach was $5,578, compared to $6,667 for the second quarter last year, a
Medifast Reports Q2 Results Read More »
Aug. 5, 2023 WW reported its second quarter results yesterday. End of Period Subscribers of 4.1 million Revenues of $226.8 million Operating Income of $26.3 million; excluding the net impact of restructuring charges and acquisition transaction costs, adjusted operating income of $33.9 million Full Year Fiscal 2023 Guidance: Revenues are expected to be in the
Weight Watchers Reports 2nd Quarter 2023 Results Read More »
January 27, 2023 Ozempic is a medication that’s designed to help manage insulin levels in people with type 2 diabetes. However, it’s recently gotten attention after some people spoke out on social media about using the drug for weight loss. Ozempic, which is a brand name for semaglutide, is currently on the Food and Drug Administration’s list of
“Ozempic Face” Side Effect Read More »
October 3, 2019 Noom has developed a weight-loss app and a personalized meal-planning service it says already is used by 45 million people worldwide that helps overweight people make behavioral changes that can help them slim down. Danish drug maker Novo says it has completed an eight-month pilot that combined Noom’s behavior change programs with
Noom and Novo Nordisk Team Up – New Diet Service Read More »